Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_2
1
50%
Ph phase_4
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

recruiting150%
not_yet_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
not_yet_recruitingphase_4

Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)

NCT06748612
recruitingphase_2

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

NCT06213506

Clinical Trials (2)

Showing 2 of 2 trials
NCT06748612Phase 4

Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)

Not Yet Recruiting
NCT06213506Phase 2

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2